Physician profile
Gary A Rosman
NPI 1548338478
$12,275.06
in general payments reported to CMS, 2019-2025
42 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,946 · 2020: $917 · 2021: $1,897 · 2022: $2,606 · 2023: $1,457 · 2024: $2,039 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,248.58 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,120.38 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $1,083.09 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $1,049.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $761.48 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $746.14 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $742.39 | 2021-2024 | Zeposia |
| Pfizer INC. | $496.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $352.16 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $253.20 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $244.15 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $239.81 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $211.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $189.81 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $161.33 | 2024-2025 | Omvoh |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $131.72 | 2022-2025 | Ibsrela |
| Shionogi INC | $119.02 | 2019-2020 | |
| Genzyme Corporation | $118.87 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $116.72 | 2024-2025 | Iqirvo |
| Karl Storz Endoscopy-America | $108.75 | 2024 | Image1 S Connect |
| Alfasigma USA, INC. | $102.53 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $90.91 | 2019-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $69.97 | 2021-2023 | Rebyota |
| Alexion Pharmaceuticals, INC. | $62.89 | 2019 | |
| Boston Scientific Corporation | $60.17 | 2021-2025 | Compliance Endokit |
| Redhill Biopharma INC. | $53.12 | 2021-2022 | |
| Ucb, INC. | $39.41 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.98 | 2019 | |
| Evoke Pharma, INC. | $29.67 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $29.66 | 2021 | |
| Dova Pharmaceuticals | $28.25 | 2019 | |
| Organon LLC | $26.76 | 2023 | Renflexis |
| Phathom Pharmaceuticals, INC. | $22.99 | 2024 | Voquezna |
| Ambu INC. | $21.93 | 2021 | |
| W. L. Gore & Associates, INC. | $19.01 | 2023 | Gore Cardioform Septal Occluder |
| Celltrion USA INC. | $18.71 | 2025 | Vegzelma |
| Allergan, INC. | $15.79 | 2020 | |
| Intra-Sana Laboratories | $14.69 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Romark Laboratories, Lc | $13.00 | 2020 | |
| Horizon Therapeutics Plc | $12.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.20 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Rosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.